Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resorantel SCHEMBL11209389 | 0.98 | TP53 (0.59) | TP53NPC1RAB9AP2RX1MAOA | |
| SCHEMBL9806572 | 0.85 | LMNA (0.65) | TP53NPC1RAB9AP2RX1MAOA | |
| SCHEMBL9806566 | 0.82 | MEN1 (0.66) | TP53P2RX1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20413311 | 0.81 | NPC1 (0.67) | TP53NPC1RAB9AP2RX1MAOB | |
| SCHEMBL10428048 | 0.81 | P2RX1 (0.57) | NPC1RAB9AP2RX1MAOBMEN1 | |
| SCHEMBL2726739 | 0.80 | HTT (0.65) | TP53NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8401776 | 0.80 | LMNA (0.74) | TP53NPC1RAB9AP2RX1MEN1 | |
| SCHEMBL8204744 | 0.80 | MEN1 (0.64) | TP53NPC1RAB9AP2RX1MEN1 | |
| SCHEMBL11857098 | 0.79 | MEN1 (0.44) | TP53NPC1RAB9AMAOAMAOB | |
| SCHEMBL8401785 | 0.77 | P2RX1 (0.74) | NPC1RAB9AP2RX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 821 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091043-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS | DATA2DISCOVERY INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4586826-A1 | FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL | In the Bowl Animal Health, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2024064209-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS | DATA2DISCOVERY, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| WO-2024059837-A1 | FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL | IN THE BOWL ANIMAL HEALTH, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| US-11166926-B2 | Compositions and methods for protecting a host from enteric toxigenic pathogens | THE HOSPITAL FOR SICK CHILDREN (CA) | 2021-11-09 | — | — | US | claimed |
| US-20200046659-A1 | COMPOSITIONS AND METHODS FOR PROTECTING A HOST FROM ENTERIC TOXIGENIC PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-02-13 | — | — | US | claimed |
| WO-2019058268-A1 | TOPICAL ANTI-INFECTIVE FORMULATION | Omnipharm Developments Limited (IE) | 2019-03-28 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-103880678-A | Benzoic acid derivative as well as preparation and hypoglycemic application thereof | CHINESE ACAD INST MICROBIOLOGY | 2014-06-25 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2004006906-A2 | METHODS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| CN-116969925-B | Heteroaryl-triazole compounds | BAYER AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| US-3987181-A | CERTAIN 2-TRIFLUOROMETHYLBENZIMIDAZOLES AS ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
| US-3934017-A | Anthelmintic composition and method utilizing isothiocyanobenzazoles active ingredients | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091043-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS | AHCY, MACO1, ME3 | TP53 616/4885NPC1 427/4885RAB9A 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.